ERBB2 and plasma cell myeloma: Hsp90 inhibition is a promising therapeutic approach in the clinic, especially in advanced stages of clinical development of specific molecular-defined subgroups of cancers (e.g., ALK-rearranged non-small-cell lung cancer, multiple myeloma and HER-2 amplified breast cancer)1, 35, 36.